As biopharma deal values climb, industry M&As are at a five-year low, not yet showing the pickup in 2022 that some analysts expected. BioWorld has recorded 330 deals, including licensings, joint ventures and collaborations, valued at $44.4 billion so far in 2022. That is a 41% increase in volume and a 31% increase in value over the same time frame last year.